Mirvedol (Memantine Hydrochloride)

Memantine hydrochloride, the active ingredient in Mirvedol, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities.

GNH USA supplies Mirvedol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive technical support and timely delivery across multiple regions.

Memantine is an NMDA receptor antagonist used in the management of neurodegenerative disorders.

Alzheimer's disease (moderate to severe): improves cognition and daily functional abilities.

Memantine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Somnolence

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Hallucinations or psychosis

Memantine should be used with caution in specific clinical situations. - Renal impairment: assess renal function and consider dose adjustment. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rate. - Concomitant anticholinergic therapy: evaluate for reduced therapeutic benefit. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism may exacerbate CNS effects. - Mannitol: may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: possible reduction in memantine efficacy. - Central nervous system depressants (e.g., benzodiazepines): may enhance dizziness or sedation.